title: Recommendations to improve identification of hereditary and familial colorectal cancer in Europe.
abstract: Familial colorectal cancer (CRC) accounts for 10-15% of all CRCs. In about 5% of all cases, CRC is associated with a highly penetrant dominant inherited syndrome. The most common inherited form of non-polyposis CRC is the Lynch syndrome which is responsible for about 2-4% of all cases. Surveillance of individuals at high risk for CRC prevents the development of advanced CRC. About 1 million individuals in Western Europe are at risk for Lynch syndrome. We performed a survey to evaluate the strategies currently used to identify individuals at high risk for CRC in 14 Western European countries. Questionnaires were distributed amongst members of a European collaborative group of experts that aims to improve the prognosis of families with hereditary CRC. The survey showed that in all countries obtaining a family history followed by referral to clinical genetics centres of suspected cases was the main strategy to identify familial and hereditary CRC. In five out of seven countries with a (regional or national) CRC population screening program, attention was paid in the program to the detection of familial CRC. In only one country were special campaigns organized to increase the awareness of familial CRC among the general population. In almost all countries, the family history is assessed when a patient visits a general practitioner or hospital. However, the quality of family history taking was felt to be rather poor. Microsatellite instability testing (MSI) or immunohistochemical analysis (IHC) of CRC are usually recommended as tools to select high-risk patients for genetic testing and are performed in most countries in patients suspected of Lynch syndrome. In one country, IHC was recommended in all new cases of CRC. In most countries there are no specific programs on cancer genetics in the teaching curriculum for medical doctors. In conclusion, the outcome of this survey and the discussions within an European expert group may be used to improve the strategies to identify individuals at high risk of CRC. More attention should be given to increasing the awareness of the general population of hereditary CRC. Immunohistochemical analysis or MSI-analysis of all CRCs may be an effective tool for identifying all Lynch syndrome families. The cost-effectiveness of this approach should be further evaluated. All countries with a CRC population screening program should obtain a full family history as part of patient assessment.
authors.affiliation: Department of Gastroenterology, Leiden University Medical Centre, 2333 AA Leiden, The Netherlands. hfavasen@stoet.nl
authors.forename: H F A
authors.initials: HF
authors.lastname: Vasen
authors.forename: G
authors.initials: G
authors.lastname: Möslein
authors.forename: A
authors.initials: A
authors.lastname: Alonso
authors.forename: S
authors.initials: S
authors.lastname: Aretz
authors.forename: I
authors.initials: I
authors.lastname: Bernstein
authors.forename: L
authors.initials: L
authors.lastname: Bertario
authors.forename: I
authors.initials: I
authors.lastname: Blanco
authors.forename: S
authors.initials: S
authors.lastname: Bulow
authors.forename: J
authors.initials: J
authors.lastname: Burn
authors.forename: G
authors.initials: G
authors.lastname: Capella
authors.forename: C
authors.initials: C
authors.lastname: Colas
authors.forename: C
authors.initials: C
authors.lastname: Engel
authors.forename: I
authors.initials: I
authors.lastname: Frayling
authors.forename: N
authors.initials: N
authors.lastname: Rahner
authors.forename: F J
authors.initials: FJ
authors.lastname: Hes
authors.forename: S
authors.initials: S
authors.lastname: Hodgson
authors.forename: J-P
authors.initials: JP
authors.lastname: Mecklin
authors.forename: P
authors.initials: P
authors.lastname: Møller
authors.forename: T
authors.initials: T
authors.lastname: Myrhøj
authors.forename: F M
authors.initials: FM
authors.lastname: Nagengast
authors.forename: Y
authors.initials: Y
authors.lastname: Parc
authors.forename: M
authors.initials: M
authors.lastname: Ponz de Leon
authors.forename: L
authors.initials: L
authors.lastname: Renkonen-Sinisalo
authors.forename: J R
authors.initials: JR
authors.lastname: Sampson
authors.forename: A
authors.initials: A
authors.lastname: Stormorken
authors.forename: S
authors.initials: S
authors.lastname: Tejpar
authors.forename: H J W
authors.initials: HJ
authors.lastname: Thomas
authors.forename: J
authors.initials: J
authors.lastname: Wijnen
authors.forename: J
authors.initials: J
authors.lastname: Lubinski
authors.forename: H
authors.initials: H
authors.lastname: Järvinen
authors.forename: E
authors.initials: E
authors.lastname: Claes
authors.forename: K
authors.initials: K
authors.lastname: Heinimann
authors.forename: J A
authors.initials: JA
authors.lastname: Karagiannis
authors.forename: A
authors.initials: A
authors.lastname: Lindblom
authors.forename: I
authors.initials: I
authors.lastname: Dove-Edwin
authors.forename: H
authors.initials: H
authors.lastname: Müller
mesh_terms: D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics; D003123:Colorectal Neoplasms, Hereditary Nonpolyposis / Q000175:diagnosis* / Q000453:epidemiology; D053843:DNA Mismatch Repair; D005060:Europe / Q000453:epidemiology; D005817:Genetic Counseling; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006287:Health Planning Guidelines; D006801:Humans; D008487:Medical History Taking; D051718:MutS Homolog 2 Protein / Q000235:genetics; D009154:Mutation; D010375:Pedigree; D012307:Risk Factors
chemical_list: D051718:MutS Homolog 2 Protein